Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for OrbusNeich Medical Group Holdings's Debt-to-Equity or its related term are showing as below:
FRA:Q8T'
s Debt-to-Equity Range Over the Past 10 Years
Min: -0.27 Med: 0.01 Max: 1.48
Current: 0.02
During the past 7 years, the highest Debt-to-Equity Ratio of OrbusNeich Medical Group Holdings was 1.48. The lowest was -0.27. And the median was 0.01.
FRA:Q8T's Debt-to-Equity is ranked better than 93.53% of 696
companies
in the Medical Devices & Instruments industry
Industry Median: 0.24
vs FRA:Q8T: 0.02
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
OrbusNeich Medical Group Holdings Debt-to-Equity Related Terms
OrbusNeich Medical Group Holdings Debt-to-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OrbusNeich Medical Group Holdings Debt-to-Equity Chart
FRA:Q8T vs ISRG, BDX, RMD: Debt-to-Equity Comparison
For the Medical Instruments & Supplies subindustry, OrbusNeich Medical Group Holdings's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
OrbusNeich Medical Group Holdings Debt-to-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, OrbusNeich Medical Group Holdings's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where OrbusNeich Medical Group Holdings's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OrbusNeich Medical Group Holdings (FRA:Q8T) has a Debt-to-Equity of 0.02 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on OrbusNeich Medical Group Holdings and its competitors. This is 100% above median its historical median of 0.01. According to the industry distribution chart, OrbusNeich Medical Group Holdings ranks #45 out of 696 companies in the Medical Devices & Instruments industry, placing it in the top 6.5%.
Is OrbusNeich Medical Group Holdings' Debt-to-Equity too high?
OrbusNeich Medical Group Holdings' current Debt-to-Equity of 0.02 is 100% above median its 10-year median of 0.01. The Medical Devices & Instruments industry median Debt-to-Equity is 0.24. OrbusNeich Medical Group Holdings' value of 0.02 is 91.7% below this industry median. Based on the distribution chart, OrbusNeich Medical Group Holdings ranks #45 out of 696 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, OrbusNeich Medical Group Holdings has a GF Score™ of 95/100, reflecting its overall financial health beyond just this single metric.
How does OrbusNeich Medical Group Holdings' Debt-to-Equity compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, OrbusNeich Medical Group Holdings ranks #45 out of 696 companies for Debt-to-Equity. This places OrbusNeich Medical Group Holdings in the top 7% of its industry — outperforming the majority of peers. The industry median Debt-to-Equity is 0.24. OrbusNeich Medical Group Holdings' value of 0.02 is 91.7% below this benchmark. While the company's 10-year median is 0.01 vs. the industry median of 0.24, OrbusNeich Medical Group Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Devices & Instruments company?
The median Debt-to-Equity among Medical Devices & Instruments companies is 0.24, based on 696 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. OrbusNeich Medical Group Holdings's current Debt-to-Equity of 0.02 is 91.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on OrbusNeich Medical Group Holdings and its competitors. For the Medical Devices & Instruments industry, the median Debt-to-Equity is 0.24 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. OrbusNeich Medical Group Holdings's current Debt-to-Equity is 0.02, which is 100% above median its own 10-year median of 0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OrbusNeich Medical Group Holdings stock overvalued right now?
OrbusNeich Medical Group Holdings (FRA:Q8T) has a current Debt-to-Equity of 0.02. The stock's GF Value™ is €0.47, compared to a current price of €0.35 — trading 25.1% below its estimated fair value. The current Debt-to-Equity is 0.02, which is 100% above median its 10-year median of 0.01 and 91.7% below the Medical Devices & Instruments industry median of 0.24. OrbusNeich Medical Group Holdings' overall GF Score™ is 95/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For OrbusNeich Medical Group Holdings (FRA:Q8T), the current Debt-to-Equity is 0.02 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is OrbusNeich Medical Group Holdings (FRA:Q8T) Overvalued in 2026?
Based on GuruFocus' analysis, OrbusNeich Medical Group Holdings stock appears to be undervalued.
The current stock price of €0.35 is trading 25.1% below its estimated GF Value™ of €0.47.
Key valuation signals for FRA:Q8T:
Debt-to-Equity: 0.02 (100% above median its 10-year median of 0.01)
GF Value™: €0.47 vs. price of €0.35 (25.1% below fair value)
Industry Position: 91.7% below the Medical Devices & Instruments median (#45 of 696)
No single metric tells the full story. See the FRA:Q8T stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
OrbusNeich Medical Group Holdings Ltd is an investment holding company. The Company principally engaged in the manufacturing, trading, sales and marketing of medical devices/instruments used for the treatment of coronary and peripheral vascular diseases. The group has only one operating segment. The company has presence in APAC, EMEA, Japan, United States, The PRC, and Others of which majority of revenue comes from APAC.
95GF Score
Get the complete analysis for FRA:Q8T
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:Q8T has been successfully added to your 
